Caring for women with breast cancer is a privilege. I am tasked with determining the very best treatment for each individual patient and working collaboratively with them on their journey.
Stanford University, Medical Oncology
Anne Favret, M.D. received her medical degree from Temple University and completed her internship and residency at Georgetown University Hospital. During her fellowship at Stanford University, she developed an interest in clinical research for breast cancer and has published several review articles, original research papers and a book chapter in the area of breast cancer management. Dr. Favret has also regularly spoken within the community and to news sources on the subject of breast cancer. In 2014, she was featured in Forbesmagazine for her expertise in breast cancer detection methods.
Dr. Favret is a member of the American Society of Clinical Oncology and stays active with tumor boards and local support groups. Having made patient care a top priority, she has received several awards throughout her career, including Top Doctor and Best Doctor honors in Washingtonian magazine, Virginia Living Magazine, and the Washington Post. Dr. Favret serves on the Executive Committee and is the Co-director of Breast Research for Virginia Cancer Specialists. She also serves on the Breast Committee for US Oncology.
Dr. Favret enjoys spending time with her family, including her three children. Her leisure time is spent cooking, running, entertaining, and going to the beach.
Northern Virginia Magazine interviews Dr. Anne Favret in their "Spotlight on Top Oncologists" February 2019Read More
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.Read More
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology PracticesRead More
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 studyRead More
Expert Insight: Genomic Variants Used To Further Stratify Risk in Breast CancerRead More
Dose intensity in early-stage breast cancer: a community practice experience.Read More
HER2-positive advanced breast cancerRead More
Multidisciplinary Management of Locally Advanced Breast CancerRead More
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)
postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)
(V3002401) ARTEST - A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining greater than or equal to 40% Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 inhibitor
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-025)